1.

Record Nr.

UNINA9910141343103321

Titolo

ATTD 2011 Year Book : Advanced Technologies and Treatments for Diabetes / / edited by Moshe Phillip, Tadej Battelino

Pubbl/distr/stampa

Chichester, West Sussex, UK ; ; Hoboken, N.J., : John Wiley & Sons, 2012

ISBN

1-280-58787-3

9786613617705

1-118-32151-0

1-118-32150-2

1-118-32152-9

Edizione

[3rd ed.]

Descrizione fisica

1 online resource (298 p.)

Altri autori (Persone)

PhillipMoshe

BattelinoTadej

Disciplina

616.462

616.46206

Soggetti

Diabetes - Treatment

Diabetics - Rehabilitation

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Description based upon print version of record.

Nota di bibliografia

Includes bibliographical references and index.

Nota di contenuto

ATTD 2011 Yearbook; Contents; List of Contributors; Preface; CHAPTER 1 Self-Monitoring of Blood Glucose; CHAPTER 2 Continuous Glucose Monitoring in 2011; CHAPTER 3 Insulin Pumps; CHAPTER 4 Closing the Loop; CHAPTER 5 New Insulins and Insulin Therapy; CHAPTER 6 New Ways of Insulin Delivery; CHAPTER 7 Using Health Information Technology to Prevent and Treat Diabetes; CHAPTER 8 Technology and Pregnancy; CHAPTER 9 Type 1 Diabetes Mellitus: Immune Intervention; CHAPTER 10 Advances in Exercise, Physical Activity and Diabetes Mellitus

CHAPTER 11 Diabetes Technology and Treatment in the Paediatric Age GroupCHAPTER 12 Diabetes Technology and the Human Factor; CHAPTER 13 New Medications for the Treatment of Diabetes; Index

Sommario/riassunto

The traditional agents for controlling the levels of glucose in the blood remain important therapies but they have their downside from the point of view of tolerability and side effects. Moreover, they appear not



to be able to counter the natural history deterioration of the disease in terms of the onset of diabetic-related complications. Recent years have seen an influx of new treatment therapies and technologies aimed at achieving better glycaemic control for diabetic patients such as liraglutide (Novo Nordisk) and saxagliptin (BMS/Astra-Zeneca) and insulin pumps, away from the more tradit